Infecciones cutáneas y de los tejidos blandos

Referencias bibliográficas: 

1 Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC Infect Dis 2015;15:362-9. doi:10.1186/s12879-015-1071-0 pmid:26293161.

2 Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis 2011;52(Suppl 7):S469-76. doi:10.1093/cid/cir162 pmid:21546623.

3 US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation Research. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf.

4 Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:e10-52. doi:10.1093/cid/ciu296 pmid:24973422.

5 Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996;23:1091-8. doi:10.1093/clinids/23.5.1091 pmid:8922808.

6 Carrel M, Perencevich EN, David MZ. USA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013. Emerg Infect Dis 2015;21:1973-80. doi:10.3201/eid2111.150452 pmid:26484389.

7 Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 2014;20(Suppl 4):3-18. doi:10.1111/1469-0691.12463 pmid:24580738.

8 Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86. doi:10.2165/11534440-000000000-00000 pmid:20426497.

9 Dalvance® (dalbavancin) [package insert]. Durata Therapeutics, 2016.

10 Jones RN, Stilwell MG. Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagn Microbiol Infect Dis 2013;76:239-40. doi:10.1016/j. diagmicrobio.2013.01.002 pmid:23414746.

11 Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013;75:304-7.doi:10.1016/j.diagmicrobio.2012.11.024 pmid:23357293.

12 Dunne MW, Sahm D, Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies. Ann Clin Microbiol Antimicrob 2015;14:19-21. doi:10.1186/s12941-015-0081-5 pmid:25885674.

13 Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis 2015;82:73-7. doi:10.1016/j. diagmicrobio.2015.01.017 pmid:25724854.

14 Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 2015;4:245-58. doi:10.1007/s40121-015-0077-7 pmid:26341488.

15 Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin fortreatment of acute bacterial skin and skin structure infection. Clin Infect Dis 2016;62:545-51. doi:10.1093/cid/civ982 pmid:26611777.

16 Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol2009;49:465-76. doi:10.1177/0091270008330162 pmid:19318696.

17 Vilay AM, Shah KH, Churchwell MD, Patel JH, DePestel DD, Mueller BA. Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif 2010;30:37-43.doi:10.1159/000316685 pmid:20588011.

18 Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 2015;45:393-8. doi:10.1016/j.ijantimicag.2014.12.021 pmid:25681068.

19 Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15. doi:10.1086/497271 pmid:16231250.

20 Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370:2169-79. doi:10.1056/NEJMoa1310480 pmid:24897082.

21 Corey GR, Kabler H, Mehra P, et al. SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370:2180-90. doi:10.1056/NEJMoa1310422 pmid:24897083.

22 Corey GR, Good S, Jiang H, et al. SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of grampositive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015;60:254-62. doi:10.1093/cid/ciu778 pmid:25294250.

23 Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015;59:864-71. doi:10.1128/AAC.03688-14 pmid:25421472.

24 Bradley JS, Puttagunta S, Rubino CM, Blumer JL, Dunne M, Sullivan JE. Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age. Pediatr Infect Dis J 2015;34:748-52.doi:10.1097/INF.0000000000000646 pmid:25551831.

25 Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54(Suppl 3):S214-9. doi:10.1093/cid/ cir920 pmid:22431851.

26 Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections. Infect Dis Ther 2016;5:1-15. doi:10.1007/s40121-016-0103-4 pmid:26831328.

27 Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationaryphase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009;53:918-25. doi:10.1128/AAC.00766-08 pmid:19104027.

28 Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). J Antimicrob Chemother 2015;70:498-504. doi:10.1093/jac/dku421 pmid:25362568.

29 Mendes RE, Sader HS, Flamm RK, Jones RN. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. J Antimicrob Chemother 2014;69:1579-81. doi:10.1093/jac/dku016 pmid:24505091.

30 Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Antimicrob Agents Chemother 2015;59:2405-9. doi:10.1128/AAC.05098-14 pmid:25666152.

31 Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR, Mendes RE. Results from oritavancin resistance surveillance programs (2011 to 2014): clarification for using vancomycin as a surrogate to infer oritavancin susceptibility. Antimicrob Agents Chemother 2016;60:3174-7. doi:10.1128/AAC.03029-15 pmid:26926647.

32 Orbactiv® (oritavancin) [package insert]. The Medicines Company, 2016.

33 Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother 2015;59:3365-72. doi:10.1128/AAC.00176-15 pmid:25824211.

34 Kumar A, Mann HJ, Keshtgarpour M, et al. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs 2011;34:1067-74. doi:10.5301/ijao.5000008 pmid:22183520.

35 Darpo B, Lee SK, Moon TE, Sills N, Mason JW. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. J Clin Pharmacol 2010;50:895-903. doi:10.1177/0091270009355449 pmid:20484618.

36 ClinicalTrials.gov. Open-label, dose-finding, pharmacokinetics, safety and tolerability study of oritavancin in  pediatric patients with suspected or confirmed bacterial infections. 2015. https://clinicaltrials.gov/ct2/show/NCT02134301.

37 ClinicalTrials.gov. Study to evaluate the safety, tolerability and pharmacokinetics of a new formulation of oritavancin in healthy volunteers. 2016. https://clinicaltrials.gov/ct2/show/NCT02471690.

38 ClinicalTrials.gov. A study to evaluate the safety of a single IV dose of Orbactiv (oritavancin) in subjects on chronic warfarin therapy being treated for acute bacterial skin and skin structure infection (ABSSSI). 2016. https://clinicaltrials.gov/ct2/show/NCT02452918.

39 Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 2015;61:1315-21. doi:10.1093/cid/civ501 pmid:26105167.

40 Rybak JM, Marx K, Martin CA. Early experience with tedizolid: Clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy 2014;34:1198-208. doi:10.1002/phar.1491 pmid:25266820.

41 Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55:5300-5. doi:10.1128/AAC.00502-11 pmid:21911576.

42 Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob 2014;13:46-52. doi:10.1186/s12941-014-0046-0 pmid:25238753.

43 Rodríguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67:167-9. doi:10.1093/jac/dkr403 pmid:21954458.

44 Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother 2016;71:152-5. doi:10.1093/jac/dkv302 pmid:26476277.

45 Sivextro® (tedizolid) [package insert]. Merck & Co, 2015.

46 Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014;42:1275-84. doi:10.1124/dmd.113.056697 pmid:24875463.

47 Bradley JS, Flanagan SD, Arrieta AC, Jacobs R, Capparelli E, Prokocimer P. Pharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescents. Pediatr Infect Dis J 2016;35:628-33. doi:10.1097/INF.0000000000001096 pmid:26910588.

48 Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55:583-92. doi:10.1128/AAC.00076-10 pmid:21115795.

49 Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother 2014;58:6471-6. doi:10.1128/AAC.03431-14 pmid:25136024.

50 Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69. doi:10.1001/jama.2013.241 pmid:23403680.

51 Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, noninferiority trial. Lancet Infect Dis 2014;14:696-705. doi:10.1016/S1473-3099(14)70737-6 pmid:24909499.

52 Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 2015;59:178-85.doi:10.1128/AAC.03684-14 pmid:25331703.

53 Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013;57:3060-6. doi:10.1128/AAC.00431-13 pmid:23612197.

54 ClinicalTrials.gov. Tedizolid tissue penetration in diabetic patients with wound infections and healthy volunteers via in vivo microdialysis. 2015. https://clinicaltrials.gov/ct2/show/NCT02620787.

55 ClinicalTrials.gov. Study of tedizolid phosphate in adolescents with complicated skin and soft tissue infections (cSSTI) (MK-1986-012). 2016. https://clinicaltrials.gov/ct2/show/NCT02276482.

56 Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther 2009;7:269-79. doi:10.1586/eri.09.7 pmid:19344241.

57 Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006;50:3882-5. doi:10.1128/AAC.00178-06 pmid:17065625.

58 Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 2006;50:2583-6. doi:10.1128/AAC.01432-05 pmid:16801451.